Programme

Program of the 22nd Thoracic Oncology Winter Symposium 2026

Session 3

Session 2

Session 1

Neoadjuvant chemoimmunotherapy in NSCL

Time: 12:40 - 13:10

Is Osimertinib still standard for EGFR mutated NSCLC?

Time: 12:10 - 12:40

Optimal usage of expensive drugs in oncology – thoughts, opinions, debate

Time: 11:40 - 12:08

CRS and other side effects in new classes of drugs/treatment

Time: 10:30 - 11:00

Biomarkers as an early detector for lung cancer

Time: 09:30 - 10:00

Closing and walking diner

Time: 13:10 - 14:00

New immunotherapy approaches: where are we with DC vaccines?

Time: 12:00 - 12:20

Targeted therapies: what’s new in EGFR KRAS, ALK ,….

Time: 11:30 - 11:32

Break

Time: 11:00 - 11:40

Antibody drug conjugates: the knew kids on the block?

Time: 10:30 - 10:38

Session 2 || Moderators:

Surgery in the era of neo-adjuvant immunotherapy

Time: 10:00 - 10:15

Chemoradiotherapy in the era of neo-adjuvant immunotherapy

Time: 09:35 - 09:45

Welcome

Time: 09:25 - 09:28

Registration

Time: 09:00 - 09:25